EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 13
Issue: 8
Year: 2026

# CLEANING VALIDATION IN THE PHARMACEUTICAL INDUSTRY: PRINCIPLES, REGULATORY REQUIREMENTS, CURRENT PRACTICES, AND RECENT ADVANCES – A REVIEW

**Priya Vaware*, Priyanka Nimbalkar, Muskan Shaikh, Mrs. Megha Hange, Dr. P. N. Sable**

Department of Pharmaceutical Quality Assurance, S.S.P. ShikhanSanstha's Siddhi College of Pharmacy, Chikhali, Pune, Maharashtra – 411062.

***Corresponding Author: Priya Vaware**

Department of Pharmaceutical Quality Assurance, S.S.P. ShikhanSanstha's Siddhi College of Pharmacy, Chikhali, Pune, Maharashtra - 411062. **DOI:** https://doi.org/10.5281/zenodo.21788371

**How to cite this Article:** Priya Vaware*, Priyanka Nimbalkar, Muskan Shaikh, Mrs. Megha Hange, Dr. P. N. Sable. (2026). Cleaning Validation In The Pharmaceutical Industry: Principles, Regulatory Requirements, Current Practices, and Recent Advances - A Review. European Journal of Biomedical and Pharmaceutical Sciences, 13(8), 257–262.


**Article Received on 05/07/2026** **Article Revised on 25/07/2026** **Article Published on 03/08/2026**

## ABSTRACT

Cleaning validation is a critical component of pharmaceutical quality assurance that ensures manufacturing equipment is consistently cleaned to predetermined acceptable levels before its reuse. In pharmaceutical manufacturing, the same equipment is frequently used for producing different products, increasing the possibility of cross-contamination, carryover of active pharmaceutical ingredients (APIs), excipients, cleaning agents, lubricants, and microbial contaminants. Such contamination may adversely affect product quality, efficacy, safety, and patient health. Therefore, regulatory authorities require scientifically documented evidence demonstrating that cleaning procedures effectively remove contaminants and maintain equipment cleanliness.[1-6] This review provides a comprehensive overview of cleaning validation, including its principles, objectives, regulatory requirements, validation lifecycle, sampling techniques, analytical methods, acceptance criteria, documentation practices, risk assessment strategies, and revalidation requirements. The review discusses recommendations from major regulatory agencies, including the US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), Pharmaceutical Inspection Co-operation Scheme (PIC/S), International Council for Harmonisation (ICH), and Indian Schedule M guidelines. Recent developments such as automated Cleaning-in-Place (CIP) systems, Process Analytical Technology (PAT), digital documentation, Health-Based Exposure Limits (HBEL), artificial intelligence (AI), and risk-based cleaning validation approaches are also highlighted.[2-8] Effective cleaning validation minimizes contamination risks, enhances regulatory compliance, improves manufacturing efficiency, reduces product recalls, and ensures patient safety. Continuous improvement, scientific risk assessment, and modern analytical technologies are expected to further strengthen cleaning validation practices in the pharmaceutical industry.[9-13]

**KEYWORDS:** Cleaning Validation, Pharmaceutical Manufacturing, Good Manufacturing Practices, Cross-contamination, Cleaning-in-Place, Swab Sampling, Rinse Sampling, HPLC, Risk Assessment, Validation.

## INTRODUCTION

The pharmaceutical industry is responsible for manufacturing medicinal products that are safe, effective, and of consistent quality. Every pharmaceutical product must comply with stringent quality standards established by national and international regulatory authorities before it reaches patients. During manufacturing, different pharmaceutical products are often produced using the same processing equipment, manufacturing lines, and packaging systems. Although this practice improves equipment utilization and reduces manufacturing costs, it also increases the risk of contamination due to residues remaining from previous products, cleaning agents, lubricants, or microorganisms. Even trace amounts of residual contaminants can affect the identity, strength, purity, and quality of subsequent products, resulting in regulatory non-compliance and potential risks to patient health.[13-16]

Cleaning validation is a documented scientific process that provides evidence that a cleaning procedure consistently removes residues from manufacturing

equipment to predetermined acceptable levels. It is an essential element of Good Manufacturing Practices (GMP) and forms an integral part of pharmaceutical quality assurance. The primary objective of cleaning validation is to ensure that manufacturing equipment is free from product residues, cleaning agent residues, microbial contamination, and other contaminants before being used for the manufacture of another product. By preventing cross-contamination and ensuring equipment cleanliness, cleaning validation contributes significantly to maintaining product quality, patient safety, and regulatory compliance.[13]

Historically, acceptance criteria for cleaning validation were based on general limits such as the 10 ppm criterion or visual cleanliness. However, advances in pharmaceutical science and toxicology have led to the adoption of more scientific approaches, including Health-Based Exposure Limits (HBEL) and Maximum Allowable Carryover (MACO), which are derived from toxicological evaluations. These approaches provide a more robust and risk-based framework for establishing acceptable residue limits.[19,20,21]

International regulatory agencies such as the US FDA, EMA, WHO, PIC/S, and the ICH have established detailed guidance for cleaning validation. These guidelines emphasize scientific justification, risk assessment, documented procedures, validated analytical methods, operator training, and continuous monitoring. Modern pharmaceutical industries increasingly employ advanced technologies, including automated Cleaning-in-Place (CIP) systems, highly sensitive analytical techniques such as High-Performance Liquid Chromatography (HPLC) and Total Organic Carbon (TOC) analysis, as well as electronic documentation systems to improve the reliability and efficiency of cleaning validation.[27-32]

In recent years, the pharmaceutical industry has adopted a lifecycle approach to validation, integrating Quality Risk Management (QRM), Process Analytical Technology (PAT), and continuous process verification into cleaning validation programs. These developments have improved process understanding, reduced validation failures, and enhanced compliance with regulatory expectations. Furthermore, digital technologies, automation, and artificial intelligence are increasingly being explored to optimize cleaning processes, monitor equipment cleanliness in real time, and facilitate data-driven decision-making.[33-37]

This review aims to provide a comprehensive overview of cleaning validation in the pharmaceutical industry by discussing its principles, regulatory requirements, validation lifecycle, contamination sources, sampling methods, analytical techniques, acceptance criteria, documentation practices, risk assessment methodologies, recent technological advances, current challenges, and future perspectives. The review is intended to serve as a valuable resource for students, researchers, quality assurance professionals, and pharmaceutical manufacturers seeking a deeper understanding of modern cleaning validation practices.[38-41]

**Need for Cleaning Validation**

Cleaning validation is an essential element of pharmaceutical quality assurance and Good Manufacturing Practices (GMP). It provides documented evidence that a cleaning process consistently removes product residues, cleaning agents, lubricants, microbial contaminants, and other impurities from manufacturing equipment to predetermined acceptable levels. The increasing use of multi-product manufacturing facilities has made cleaning validation a regulatory requirement to prevent cross-contamination and ensure the production of safe and effective medicines.

In pharmaceutical industries, the same equipment is often used to manufacture different products. If equipment is not cleaned properly after one production batch, residues may remain on equipment surfaces and contaminate the next product. Such contamination may alter the quality, safety, identity, strength, purity, or efficacy of the subsequent product, posing significant risks to patient health.

Cleaning validation is also essential for ensuring compliance with international regulatory authorities such as the US FDA, EMA, WHO, PIC/S, and Schedule M. These agencies require manufacturers to establish scientifically justified cleaning procedures and validate them before routine implementation. Failure to comply with cleaning validation requirements may result in regulatory observations, warning letters, product recalls, production delays, financial losses, and damage to the manufacturer's reputation.

Another important reason for cleaning validation is to verify the effectiveness and reproducibility of cleaning procedures. A validated cleaning process ensures that every cleaning cycle consistently achieves the required cleanliness level, regardless of the operator or manufacturing batch. This improves process reliability and minimizes the possibility of human error.

Cleaning validation also contributes to reducing manufacturing costs by minimizing product rejection, equipment downtime, repeated cleaning, and unnecessary investigations. Proper cleaning procedures extend equipment life, improve production efficiency, and reduce environmental pollution by optimizing the use of cleaning agents and water.

Moreover, cleaning validation supports risk management by identifying critical equipment, difficult-to-clean locations, worst-case products, and potential contamination sources. The adoption of risk-based cleaning validation and Health-Based Exposure Limits

(HBEL) has further strengthened patient protection by establishing scientifically justified residue limits.

**Importance of Cleaning Validation**

- Cleaning validation plays a vital role in pharmaceutical manufacturing because it:
- Prevents cross-contamination between different pharmaceutical products.
- Ensures the removal of active pharmaceutical ingredient (API) residues.
- Removes excipients, detergents, lubricants, and cleaning agents.
- Reduces microbial contamination.
- Protects patient safety and product quality.
- Ensures compliance with GMP and regulatory requirements.
- Improves manufacturing consistency and process reliability.
- Reduces product recalls and regulatory observations.
- Enhances equipment utilization and operational efficiency.
- Supports quality risk management and continuous improvement.

**Objectives of Cleaning Validation**

The primary objective of cleaning validation is to demonstrate, through documented scientific evidence, that a cleaning procedure consistently removes all residues from manufacturing equipment to predetermined acceptable limits. A successful cleaning validation program ensures that equipment can be safely reused for the manufacture of another product without affecting its quality or safety.

The specific objectives are as follows:

1. To Prevent Cross-Contamination : The foremost objective is to eliminate the possibility of transferring residues from one product to another during manufacturing.
2. To Ensure Product Quality: Validated cleaning procedures ensure that pharmaceutical products consistently meet predefined quality specifications for identity, purity, strength, and safety.
3. To Protect Patient Safety: Removal of harmful residues prevents accidental exposure of patients to active pharmaceutical ingredients, allergens, toxic substances, or microorganisms.
4. To Demonstrate Cleaning Effectiveness: Cleaning validation provides scientific evidence that the selected cleaning procedure effectively removes contaminants from equipment surfaces.
5. To Comply with Regulatory Requirements: Cleaning validation ensures compliance with GMP guidelines and regulatory expectations issued by agencies such as the FDA, EMA, WHO, PIC/S, and Schedule M.
6. To Establish Scientifically Justified Acceptance Limits: Cleaning validation establishes acceptable residue limits based on toxicological evaluation, Health-Based Exposure Limits (HBEL), Maximum Allowable Carryover (MACO), and product-specific characteristics.
7. To Standardize Cleaning Procedures: Validation ensures that cleaning procedures are standardized, reproducible, and consistently followed by trained personnel.
8. To Improve Manufacturing Efficiency: Validated cleaning procedures reduce production downtime, eliminate unnecessary repeat cleaning, and improve equipment availability.
9. To Support Quality Risk Management: Cleaning validation identifies critical process parameters, worst-case products, difficult-to-clean equipment, and potential contamination risks, enabling appropriate risk control measures.
10. To Maintain Documentation and Traceability: Cleaning validation generates complete documentation, including validation protocols, sampling records, analytical reports, deviations, corrective actions, and validation reports, ensuring traceability and regulatory compliance.

- Benefits of Cleaning Validation
- Ensures consistent product quality.
- Enhances patient safety.
- Prevents product mix-ups and contamination.
- Meets global regulatory requirements.
- Reduces manufacturing costs.
- Minimizes product recalls.
- Improves equipment performance.
- Supports continuous quality improvement.
- Increases confidence during regulatory inspections.
- Strengthens the pharmaceutical qua. Regulatory Guidelines for Cleaning Validation

Cleaning validation is a mandatory requirement under Good Manufacturing Practices (GMP) and is regulated by several national and international regulatory agencies. These agencies have issued guidelines to ensure that pharmaceutical manufacturing equipment is cleaned effectively and consistently, thereby preventing cross-contamination and ensuring patient safety. Although the terminology and specific requirements may vary, all regulatory bodies emphasize that cleaning procedures must be scientifically justified, validated, documented, and periodically reviewed.

**United States Food and Drug Administration (US FDA)**

The US FDA was one of the first regulatory authorities to publish guidance on cleaning validation through its Guide to Inspections of Validation of Cleaning Processes (1993). This guidance remains one of the most widely referenced documents in the pharmaceutical industry.

**According to the FDA**

- Cleaning procedures should be validated before routine implementation.
- Written Standard Operating Procedures (SOPs) must be available for cleaning activities.

- Cleaning validation should provide documented evidence that residues are consistently removed to acceptable levels.
- Acceptance limits should be scientifically justified and based on product characteristics and toxicological data.
- Appropriate analytical methods with adequate sensitivity and specificity should be used to detect residues.
- Validation studies should include worst-case conditions, such as the least soluble product, most potent drug, or hardest-to-clean equipment.
- Any deviations observed during validation should be investigated and corrective and preventive actions (CAPA) implemented.
- The FDA also encourages manufacturers to adopt Quality Risk Management (QRM) principles when designing cleaning validation programs.

**World Health Organization (WHO)**

The WHO Good Manufacturing Practices (GMP) guidelines emphasize that pharmaceutical equipment must be thoroughly cleaned and maintained to prevent contamination and ensure product quality.

- WHO recommends that manufacturers:
- Develop scientifically justified cleaning procedures.
- Validate all cleaning processes before routine production.
- Establish written cleaning protocols and documentation.
- Monitor equipment cleanliness regularly.
- Train personnel involved in cleaning activities.
- Periodically review cleaning validation programs to ensure continued effectiveness.
- WHO also stresses the importance of cleaning validation in multi-product manufacturing facilities where the risk of cross-contamination is high.

**European Medicines Agency (EMA)**

The European Medicines Agency (EMA) introduced a more scientific and risk-based approach through its guideline on Health-Based Exposure Limits (HBELs).

**EMA recommends**

Establishing cleaning limits based on toxicological evaluations rather than fixed limits such as the traditional 10 ppm criterion.

- Performing detailed risk assessments for all products manufactured on shared equipment.
- Using Permitted Daily Exposure (PDE) values to calculate acceptable residue limits.
- Applying scientifically justified cleaning procedures supported by validated analytical methods.
- Periodically reviewing cleaning validation based on manufacturing experience and process changes.
- The EMA guideline has significantly influenced modern cleaning validation practices by encouraging manufacturers to adopt health-based acceptance criteria.

Pharmaceutical Inspection Co-operation Scheme (PIC/S)

PIC/S provides internationally recognized GMP guidelines followed by many regulatory authorities worldwide.

**According to PIC/S**

- Cleaning validation should be based on scientific evidence and risk assessment.
- Equipment should be designed to facilitate effective cleaning.
- Worst-case product selection should be scientifically justified.
- Cleaning procedures should be standardized and reproducible.
- Validation reports should include protocols, analytical results, deviations, and conclusions.
- Cleaning validation should be reviewed periodically to ensure continued effectiveness.
- PIC/S also encourages continuous improvement of cleaning validation programs.

**International Council for Harmonisation (ICH)**

Although the ICH has not published a dedicated cleaning validation guideline, several ICH guidelines support cleaning validation practices.

- ICH Q9 – Quality Risk Management
- ICH Q9 recommends:
- Identifying potential contamination risks.
- Assessing product toxicity.
- Evaluating equipment design.
- Prioritizing critical cleaning processes.
- Implementing appropriate risk control measures.
- Risk assessment tools commonly used include:
- Failure Mode and Effects Analysis (FMEA)
- Hazard Analysis and Critical Control Points (HACCP)
- Risk Ranking and Filtering
- ICH Q10 – Pharmaceutical Quality System
- ICH Q10 emphasizes:
- Lifecycle management of cleaning validation.
- Change management.
- Corrective and Preventive Actions (CAPA).
- Continuous process verification.
- Documentation and management review.
- These principles ensure that cleaning validation remains effective throughout the product lifecycle.

**Schedule M (India)**

In India, Schedule M of the Drugs and Cosmetics Rules, 1945, specifies GMP requirements for pharmaceutical manufacturing.

**Schedule M requires manufacturers to**

- Clean manufacturing equipment after every production batch.
- Validate cleaning procedures for shared equipment.
- Maintain written SOPs and cleaning records.

- Prevent cross-contamination between products.
- Ensure that cleaning agents do not leave harmful residues.

**Comparison of Major Regulatory Guidelines**

| Sr.no. | Regulatory Agency | Main Focus |
|---|---|---|
| 1. | US FDA | Validation Of Cleaning Process |
| 2. | WHO | GMP compliance |
| 3. | EMA | Health – Based Exposure Limits (HBEL) |
| 4. | PIC/ S | Risk- Based Cleaning Validation |
| 5. | ICH Q 9 | Quality Risk Management |
| 6. | ICH Q 10 And Schedule M | Pharmaceutical Quality System And Indian GMP |

**REFERENCE**


1. United States Food and Drug Administration. **Guide to inspections of validation of cleaning processes**. Silver Spring (MD): US Food and Drug Administration, 1993.
2. European Medicines Agency. **Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012)**. London: European Medicines Agency, 2014.
3. Pharmaceutical Inspection Co-operation Scheme (PIC/S). **PI 006-3: Recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation**. Geneva: PIC/S, 2007.
4. World Health Organization. **WHO good manufacturing practices for pharmaceutical products: main principles. Annex 2**. WHO Technical Report Series No. 986. Geneva: World Health Organization, 2014.
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). **ICH Q9(R1): Quality risk management**. Geneva: ICH, 2023.
6. Central Drugs Standard Control Organization. **Revised Schedule M: Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products**. New Delhi: Ministry of Health and Family Welfare, Government of India, 2024.
7. Fourman GL, Mullen MV. Determining cleaning validation acceptance limits for pharmaceutical manufacturing operations. **Pharm Technol,** 1993; 17(4): 54-60.
8. Agalloco J, Akers J, Madsen R. **Validation of pharmaceutical processes: from design to commercial manufacture**. 4th ed. Boca Raton (FL): CRC Press, 2021.
9. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q9(R1): Quality risk management. Geneva: ICH, 2023. Available from: https://www.ich.org/page/quality-guidelines
10. European Medicines Agency. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012). London: European Medicines Agency, 2014.
11. Pharmaceutical Inspection Co-operation Scheme (PIC/S). PI 006-3: Recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation. Geneva: PIC/S, 2007.
12. Fourman GL, Mullen MV. Determining cleaning validation acceptance limits for pharmaceutical manufacturing operations. Pharm Technol, 1993; 17(4): 54-60.
13. United States Food and Drug Administration. Guide to inspections of validation of cleaning processes. Silver Spring (MD): US Food and Drug Administration, 1993.
14. European Medicines Agency. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012). London: European Medicines Agency, 2014.
15. Pharmaceutical Inspection Co-operation Scheme (PIC/S). PI 006-3: Recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation. Geneva: PIC/S, 2007.
16. World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series No. 986, Annex 2. Geneva: World Health Organization, 2014.
17. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q9(R1): Quality risk management. Geneva: ICH, 2023.
18. LeBlanc DA. Establishing scientifically justified acceptance criteria for cleaning validation of finished drug products. Pharm Technol, 2000; 24(10): 136-148.
19. European Medicines Agency. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. London: EMA; 2014. EMA/CHMP/CVMP/SWP/169430/2012. Available from: EMA Guideline on Health-Based Exposure Limits

20. European Medicines Agency. Questions and answers on implementation of risk-based prevention of cross-contamination in production and "Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities". London: EMA; 2018. Available from: EMA Q&A on HBEL and Cleaning Limits.
21. Pharmaceutical Inspection Co-operation Scheme (PIC/S). PIC/S Guide to Good Manufacturing Practice for Medicinal Products, Annex 15: Qualification and Validation. Geneva: PIC/S, 2018. PI 006-3.
22. Health Canada. Cleaning validation guide (GUI-0028). Ottawa: Health Canada; 2021. Available from: Health Canada Cleaning Validation Guide (GUI-0028)US Food and Drug Administration. Guide to inspections of validation of cleaning processes. Silver Spring (MD): US FDA, 1993.
23. European Medicines Agency. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. London: EMA; 2014. EMA/CHMP/CVMP/SWP/169430/2012.
24. World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series No. 1033, Annex 2. Geneva: World Health Organization, 2021.
25. Pharmaceutical Inspection Co-operation Scheme. PIC/S Guide to Good Manufacturing Practice for Medicinal Products, Annex 15: Qualification and Validation. PI 006-3. Geneva: PIC/S, 2018.
26. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q9(R1): Quality Risk Management. Geneva: ICH, 2023.
27. Health Canada. Cleaning validation guidelines (GUI-0028). Ottawa (ON): Health Canada, 2021.
28. US Food and Drug Administration. Guide to inspections of validation of cleaning processes. Silver Spring (MD): US FDA, 1993.
29. European Medicines Agency. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. London: EMA, 2014. EMA/CHMP/CVMP/SWP/169430/2012.
30. World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series No. 1033, Annex 2. Geneva: World Health Organization, 2021.
31. Pharmaceutical Inspection Co-operation Scheme. PIC/S Guide to Good Manufacturing Practice for Medicinal Products, Annex 15: Qualification and Validation. PI 006-3. Geneva: PIC/S, 2018.
32. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q9(R1): Quality Risk Management. Geneva: ICH, 2023.
33. Health Canada. Cleaning validation guidelines (GUI-0028). Ottawa (ON): Health Canada, 2021.
34. US Food and Drug Administration. Guidance for Industry: Process Validation: General Principles and Practices. Silver Spring (MD): US Food and Drug Administration, 2011.
35. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q9(R1): Quality Risk Management. Geneva: ICH, 2023.
36. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q10: Pharmaceutical Quality System. Geneva: ICH, 2008.
37. US Food and Drug Administration. Guidance for Industry: PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Silver Spring (MD): US Food and Drug Administration, 2004.
38. Pharmaceutical Inspection Co-operation Scheme. PIC/S Guide to Good Manufacturing Practice for Medicinal Products, Annex 15: Qualification and Validation. PI 006-3. Geneva: PIC/S, 2018.
39. US Food and Drug Administration. Guide to inspections of validation of cleaning processes. Silver Spring (MD): US Food and Drug Administration, 1993.
40. Pharmaceutical Inspection Co-operation Scheme. PIC/S Guide to Good Manufacturing Practice for Medicinal Products, Annex 15: Qualification and Validation. PI 006-3. Geneva: Pharmaceutical Inspection Co-operation Scheme, 2018.
41. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q9(R1): Quality Risk Management. Geneva: ICH, 2023.
42. Health Canada. Cleaning validation guidelines (GUI-0028). Ottawa (ON): Health Canada, 2021.